Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

4D Molecular Therapeutics (FDMT) Gains from Sales and Divestitures (2024 - 2025)

4D Molecular Therapeutics (FDMT) has disclosed Gains from Sales and Divestitures for 2 consecutive years, with $158231.0 as the latest value for Q4 2025.

  • Quarterly Gains from Sales and Divestitures rose 199.2% to $158231.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $158231.0 through Dec 2025, up 199.2% year-over-year, with the annual reading at $158231.0 for FY2025, 199.2% up from the prior year.
  • Gains from Sales and Divestitures for Q4 2025 was $158231.0 at 4D Molecular Therapeutics, up from $113785.0 in the prior quarter.
  • The five-year high for Gains from Sales and Divestitures was $158231.0 in Q4 2025, with the low at $10996.0 in Q1 2024.